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The aim of the study was to compare standards for the process of care and 2-year survival between two cohorts of patients with
head and neck cancer in the south and west of England. A total of 566 and 727 patients presented in 1996–97 and 1999–2000,
respectively. The median number of cases treated per surgeon was 4 (1997, range 1–26) and 4 (2000, 1–23) and per radiotherapist
was 10 (1–51) and 19 (1–70). For all ‘nontemporal’ standards, the overall standard increased, without reaching minimum high
targets, while most ‘waiting times’ increased. Overall 2-year survival was 64.1% in 1997 and 65.1% in 2000. There was no difference in
survival between networks (range 56–68, 1997, log-rank test 4.1, P¼0.4; 62–69, 2000, log-rank test 1.26, P¼0.69). Patients
assessed by a multidisciplinary clinic exhibited improved survival (1997: P¼0.1; 2000: hazard ratio 0.7, P¼0.02), as did those with a
pretreatment chest X-ray (hazard ratio 0.7, P¼0.03). Despite an increased incidence, standards for the process of care for patients
with head and neck cancer improved between 1996 and 2000, while waiting times increased and 2-year survival rates remained
unaltered. Two out of five networks demonstrated centralisation of services between audits. Being seen in a multidisciplinary clinic
correlated strongly with patient survival.
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In 1998, we released the first report of the South and West Audit of
Head and Neck Cancer, SWAHN I (Birchall et al, 2000). Data
collection for this had begun in 1996 and clinicians and hospitals
barely had time to respond to the changes recommended by the
Calman–Hine report (Expert Advisory Group on Cancer, 1995).
Those changes were not clearly stated, and there was widespread
scepticism that clinicians had been doing things wrongly in the
first place and there was no explicit funding for change. This audit,
based on standards developed by a formal consensus method
(Birchall, 1998; Wilson, 2003), benchmarked how UK head and
neck services were performing in the period leading up to the
‘reforms’. Since then, central funding has been released with the
intention of improving standards in cancer care (Department of
Health, 2002), although how much of this has reached head and
neck services on the ground is unclear.
A repeat of the audit in 1999–2000, SWAHN II (Birchall and
Bailey, 2001), presented the opportunity to examine whether
standards in head and neck cancer care in the UK had improved
post-Calman–Hine and whether this was accompanied by
improved survival.
MATERIALS AND METHODS
The same population (6.5 millions) was examined by both audits,
with the exception of one hospital, which had only diagnosed three
cases in the first study. ‘Cases’ were all those patients diagnosed
with a primary head and neck cancer between 1st December 1996
and 30th November 1997 (SWAHN I) and 1st September 1999 to
31st August 2000 (SWAHN II). Skin, lip, thyroid cancer and
lymphomas were excluded.
New cases were identified by clinicians within each Trust and
details recorded on a paper proforma that included demographic
details and fields corresponding to each of the consensus
standards for the process of care (Birchall, 1998). Internal audit
and peer-review methods assured accuracy and validity of
information received. Computerised validation checks identified
erroneous data entries. Comparison with the Cancer Register and
with pathology records for all cancer cases, routinely forwarded
monthly by each Trust, was performed. Where further cases found,
reminders were sent to the relevant clinician. A final quality check
was performed by arbitrary sampling of case notes. In 2003, lists of
all cases entered into the audit were sent to Trusts. Information
was requested on whether the patient was alive or dead, date of
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lloco-regional recurrence and death and recorded cause of death.
Deaths were then crosschecked with the cancer registry.
Kaplan–Meier survival analysis was carried out (SPSS, SPSS Corp.,
USA). Univariate analysis for significant differences in distribution
between groups used log-rank tests. Multivariate analysis of survival
against case-mix and standards used Cox proportional hazards.
RESULTS
Distribution of cases
The number of cases for which complete data were obtained
increased from 566 in 1997 to 727 in 2000, that is, an increase of
29%. The number of cases predicted from registry figures for the
corresponding years was 650 and 768 respectively (an increase of
18%), giving predicted capture rates of 87 and 95% respectively (an
increase of 8% between audits). Male:female distribution remained
at 2:1, but there was a slight trend towards younger age-groups
(45–64 group increased from 34 to 38%, 65–74 group decreased
from 32 to 26%). There was a nonsignificant increase in oral cancer
(30–33%) and a decrease in laryngeal cancer (32–26%), but no
change in the proportion of cases with each UICC stage.
Treatment
Proportions receiving surgery (50 and 47%), radiotherapy (69 and
68%) and chemotherapy (7.4 and 8.5%; Table 1) were similar.
There was a nonsignificant increase in use of radiotherapy as sole
treatment for laryngeal and pharyngeal cancers (80 and 50% in
SWAHN I compared to 95 and 70% in SWAHN II). The use of
partial (mainly endoscopic) surgery for laryngeal tumours
increased from 20% of operations to 25%. The median number
of cases treated per surgeon in 1997 was 4 (range 1–26) and this
was unchanged in 2000 (4, 1–23). However, the number per
consultant radiotherapist increased from 10 (1–51) to 19 (1–70)
between audits. The degree of ‘centralisation’ of treatment between
1997 and 2000 varied considerably between networks. For central
south coast, the number of treating hospitals decreased from six
to two and for Dorset from two to one, whereas the other three
networks showed no obvious change in referral patterns (Figure 1).
Standards
For all ‘nontemporal’ standards, the overall standard increased,
although without reaching the established ‘minimum high’
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Figure 1 Number of head and neck cancer patients diagnosed and treated by hospital Trust in (A) central south coast and (B) Avon Somerset and
Wiltshire cancer networks. (A) shows evidence of centralisation, while (B) does not. Other networks showed similar results to (B).
Table 1 Chemotherapy use in SWAHN I and SWAHN II, showing
intent and method of treatment
Treatment
intent
Total
number
Number
neoadjuvant
Number
concurrent
Number single
modality
SWAHN I
Palliative 10 3 4 3
Curative 29 12 14 3
Not stated 3 1 2 1
Total 42 16 20 7
SWAHN II
Palliative 16 8 3 5
Curative 38 7 25 6
Not stated 8 3 3 2
Total 62 18 31 13
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ltargets (defined as ‘the lowest level compatible with something
that a body of experts would regard as high quality care’; Table 2).
Most marked was the increase in the proportion of patients
assessed at multidisciplinary clinics (46–74%, standard
95%). These were defined as clinics where the patient was assessed
by at least one consultant oncologist and radiotherapist and
one head and neck surgeon. Pretreatment chest X-rays also
increased from 52 to 68% (standard 100%), while the proportion
of advanced (T3/T4) stage tumours receiving MRI or CT scan
grew from 56 to 78% (target 90%). In 83% of cases in 1997
and 87% in 2000 (target 100%), tumour, node, metastasis (TNM)
staging was achieved.
Times between activities
A consensus pathway for the process of care and standards for the
intervals along this pathway had previously been determined
(Birchall, 1998). For a few parts of the pathway, ‘waiting’ times
remained constant, but most increased between 1997 and 2000
(Table 3). While the time between general practitioner (GP) letter
and first outpatient visit remained short for oral cancer (10 days
both audits), it remained long for laryngeal cancer (21 days both
audits; target 14 days). However, the range diminished for
both between audits. Median times between first hospital visit
and definitive surgery increased from 26 to 28 days for laryngeal
cancer and 29 to 38 days for oral cancer. For radiotherapy,
corresponding waits were 56 and 64 days (larynx) and 42 and 47.5
days (oral cavity).
2-year survival
Comparison between 2-year survival figures for SWAHN I
and SWAHN II is shown in Table 4. Overall crude survival
was 64.1% in 1997 and 65.1% in 2000. In both cohorts, survival
was significantly affected by age, stage and site. For both SWAHN I
and II, 2-year survival was significantly better if patients
took longer between GP letter and first outpatient visit than the
government’s target time of 2 weeks (or 10 working days). A
Cox proportional hazard analysis of SWAHN I 2-year survival
data showed a marked trend towards improved survival if
the patient had been assessed in a multidisciplinary clinic
(P¼0.1). However, survival was significantly higher for
those who had had a pretreatment chest X-ray (hazard ratio 0.7,
P¼0.03). A similar analysis of SWAHN II 2-year survival
data showed significantly improved survival for patients
assessed in a multidisciplinary clinic (hazard ratio 0.7, P¼0.02)
and those receiving a pretreatment chest X-ray (hazard ratio
0.7, P¼0.03).
There was no significant difference in 2-year survival in either
cohort with respect to age, sex or cancer network. A significant
improvement in survival was indicated for stage II disease (68.2%
in 1997, 81% in 2000, log-rank test 4.5, P¼0.03) and for laryngeal
carcinoma (72.1% in 1997, 84.7 in 2000, log-rank test 8.41,
Po0.01). However, this latter improvement did not persist
when multiregression analysis was conducted to take account
of case-mix.
Quality of life
No patients in SWAHN I had quality of life measurements
recorded. In the second cohort, 32 of 727 cases had such
measurements, all using the EORTC head and neck tool.
DISCUSSION
Principal findings
In the south and west of England in the late 1990s, there was an
improvement in standards for the process of head and neck cancer
care as measured against consensus standards. The biggest
improvement was in the number of patients being assessed in a
multidisciplinary clinic. However, ‘waiting’ times increased. There
was increasing experience among radiotherapists, but for surgeons
the median number of cases treated annually remained 4. Only one
network showed evidence of ‘centralisation’ of treatment. Of the
five ‘key quality indicators’ studied, assessment at a multi-
disciplinary clinic and performance of a pretreatment chest
Table 2 Comparison between nontemporal standards achieved and
target standards in SWAHN I and SWAHN II
Standard
SWAHN I SWAHN II
Target
standard (%) n % n %
Patients seen at a combined clinic 566 46 727 74 95
Having an X-ray 566 52 727 68 100
Advanced T3/T4 larynx and oral
tumours having a pretreatment
MRI/CT scan
126 56 156 78 90
TNM staging 566 83 727 87 100
MRI¼magnetic resonance imaging; CT¼computerised tomography; TNM¼
tumour, node, metastasis.
Table 3 Comparison between temporal standards achieved and target standards in SWAHN I and SWAHN II
SWAHN I SWAHN II
Standard n Median (days) n Median (days) Target standard (days)
GP/GDP letter to first outpatient appointment – laryngeal cancers 143 21 160 21 14
GP/GDP letter to first outpatient appointment – oral cancers 146 11 201 11 14
First outpatient appointment to joint head and neck clinic – laryngeal cancers 77 28 122 30 14
First outpatient appointment to joint head and neck clinic – oral cancers 87 14 167 18 14
First outpatient appointment to surgery – laryngeal cancers 37 26 29 28
First outpatient appointment to surgery – oral cancers 103 29 140 38
First outpatient appointment to radiotherapy – laryngeal cancers 84 56 125 64
First outpatient appointment to radiotherapy – oral cancers 34 42 56 48
GP¼general practitioner; GDP¼general dental practitioner.
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There was no significant difference in outcomes between cancer
networks.
Weaknesses
There was probably incomplete coverage, as numbers fell short of
actual death registrations. Both were paper-based exercises, and
not all questionnaires were completed by consultants, which may
have introduced errors despite attempts at quality control.
Performance status has major effects on survival but was rarely
reported and the external validity of the chosen system is now
doubtful (Aronson et al, 2003). Likewise, the low rates of recording
of quality of life (0 and 4% respectively) made assessment of the
effect of performance improvements on this important measure
impossible. It was not the intent of this study to investigate
treatment morbidity, and this should be addressed by future
audits. Assessing survival at 2 years may be seen as premature.
However, a 5-year analysis for patients in SWAHN I (data not
shown) shows that the trends at 2 years exactly reflect those at 5
years. Skin, lip and thyroid cancer cases are important parts of
head and neck oncology workload, but the consensus view was that
the management of these cases was distinct from that of ‘core’ head
and neck cancers.
The cost of collecting data was d40.00 per case in 1997 and
d50.00 per case in 2000. The provision of a national, centralised
electronic data collection system, presently being piloted, may
reduce these per capita costs significantly in the future.
Standards
It was gratifying that there had been a rapid increase in all
nontemporal standards between 1997 and 2000, especially access to
multidisciplinary clinics. However, in all consensus documents on
cancer (Expert Advisory Group on Cancer, 1995; Wilson, 2003),
such access is regarded as a fundamental right, so there is still
considerable scope for improvement. Similarly, it is difficult to see
how an accurate treatment plan may be drawn up in the absence of
TNM staging (more than 10%). The use of chemotherapy outside
clinical trials is common (one in 11 patients) with little
standardisation of protocols.
Process times
Increases in process time were also worrying. One explanation is
the increase in resource use, particularly radiology, pathology and
theatre access, required to comply with care standards. This would
be exacerbated by ‘creeping centralisation’ into fewer centres,
which are not adequately funded to support this change. However,
only two networks showed signs of having centralised in this way,
and, probably as a result, the number of patients treated per
clinician remained as tiny as in a 1997 study (Edwards et al, 1997).
The use of care/critical pathway techniques (Wheelwright et al,
2002) might help identify where the rate-limiting steps are
occurring in each Trust. Alternatively, the provision of more
facilities by the recent cash injection into cancer services may have
shortened times post-2000 (Department of Health, 2002). The next
audit cycle should shed light on this.
2-year survival rates
The 2-year survival rates for the south and west of England are
comparable to those published for the USA (Shirinian et al, 1994;
Rosenthal et al, 2002) and the UK (Robin et al, 1991; Woolgar et al,
1999). Since the ‘quality’ of care in the region appeared to have
improved between 1997 and 2000, it was disappointing that this
was not reflected in improved survival figures overall. It is possible
that gains achieved by better radiology, endoscopy, staging and
multidisciplinary planning were offset by lengthened waiting
times for investigation and treatment: ‘delays’ in treatment
have been previously shown to affect survival adversely (Rosenthal
et al, 2002).
It is presently mandatory for all hospital Trusts to produce
regular data on the proportions of suspected cancer patients being
seen by a specialist within 2 weeks of GP referral as a major
performance target. However, we found that, in practice, being
seen within the government’s 2-week target time resulted in a
significantly poorer survival rate at 2 years. Further analysis of
these data showed that this was explained by a trend towards
higher tumour stage in the 2-week group compared to those
waiting longer. This is a reasonable explanation as it is easier for
general practitioners to ‘spot’ bigger tumours than small ones with
often vague symptoms. However, these data cast a slight shadow
over the Government’s reliance on this temporal target.
A trend in SWAHN I towards improved survival if patients had
been assessed before treatment in a multidisciplinary clinic
became significant in SWAHN II. The need for multidisciplinary
assessment in cancer care has been a clarion call, despite
difficulties in designing trials to prove its worth (Hanks et al,
Table 4 Kaplan–Meier crude survival at 2 years – comparison between
SWAHN I and SWAHN II, including comparison between individual cancer
networks
2-year survival –
SWAHN I
2-year survival –
SWAHN II
Survival
Confidence
intervals Survival
Confidence
intervals
%%%%
Overall 64.1 60.2–68.0 65.1 61.6–68.6
Age group (years)
0–64 74.8 69.1–80.5 70.6 65.7–75.5
65–74 62.5 55.2–69.8 65.3 58.2–72.4
75+ 51.2 43.6–58.8 57.0 50.5–63.5
Sex
Male 66.6 61.7–71.5 65.5 61.2–69.8
Female 59.9 53.2–66.6 64.2 58.1–70.3
Stage
I 89.8 84.3–95.3 87.0 81.5–92.5
II 68.2 58.2–78.2 81.0 74.1–87.9
III 55.3 45.3–65.3 60.2 51.2–69.2
IV 46.8 39.4–54.2 45.6 39.3–51.9
Unknown 68.8 59.6–78.0 67.7 58.1–77.3
Site
Larynx 72.1 65.4–78.8 84.7 79.6–89.8
Oral 62.4 55.1–69.7 62.2 56.1–68.3
Pharynx 51.3 42.3–60.3 50.1 42.3–57.9
Salivary gland 72.0 59.5–84.5 69.6 57.6–81.6
Other 64.6 51.1–78.1 51.9 40.9–62.9
Network
Three counties 63.4 52.2–74.6 67.6 58.8–76.4
ASWCS 59.7 50.9–68.5 62.9 56.2–69.6
Central south coast 66.9 59.3–74.5 68.7 61.6–75.8
Dorset 55.9 43.2–68.6 61.8 48.9–74.7
Peninsula 68.1 61.0–75.2 63.7 56.8–70.6
Waiting times – GP to
outpatient (weeks)
o2 59.0 52.5–65.5 61.0 55.1–66.9
42 70.7 64.8–76.6 71.9 66.8–77.0
ASWCS¼Avon, Somerset and Wiltshire Cancer Services.
Head and neck cancer, standards and survival
M Birchall et al
1480
British Journal of Cancer (2004) 91(8), 1477–1481 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l2002). This is the first time a significant impact of such clinics on
survival has been demonstrated for head and neck oncology.
We have also twice demonstrated an unexpected association
between the performance of a pretreatment chest X-ray and
improved survival. Possible explanations for this include missing
significant chest disease, the use of CT scans in advanced disease
or X-ray use being a surrogate marker of ‘quality’ of care.
Meaning of the study
We have measured improvement in the quality of the care process
for patients with head and neck cancer in southwest England.
However, lengthened process time may have prevented this
being translated into improved survival. Policy makers must plan
for the knock-on effects of adherence to quality standards and
increasing centralisation of care. At present, both are happening
without the necessary plans and funds to accommodate them.
The survival advantage gained by persons assessed in a multi-
disciplinary manner strongly supports the end of single clinician
practice.
Unanswered questions and future research
Future studies will examine whether these trends for standards and
centralisation continue and are translated to increased 2- and 5-
year survival. Other studies should address the reasons for the
increasing incidence of this cancer and perform more detailed
examinations of the effect service configuration has on patient
outcomes.
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